Progress and harmonization of gene editing to treat human diseases: Proceeding of COST Action CA21113 GenE-HumDi
Metadatos
Mostrar el registro completo del ítemAutor
Cavazza, Alessia; González Martínez, Coral; Sánchez Martín, Rosario María; Martín Molina, Francisco; Benabdellah, Karim; COST Action CA21113Editorial
Elsevier
Fecha
2023-12-12Referencia bibliográfica
Cavazza, A. et al. Progress and harmonization of gene editing to treat human diseases: Proceeding of COST Action CA21113 GenE-HumDi. Molecular Therapy: Nucleic Acids Vol. 34 December 2023. [https://doi.org/10.1016/j.omtn.2023.102066]
Patrocinador
COST (European Cooperation of Science and Technology); Consejería de Universidad, Investigación e Innovación, Junta de Andalucía PAIDI 2020, ProyExcel_00875; Junta de Andalucia/FEDER (PECART-0027-2020); Consejería de Salud y Consumo de la Junta de AndalucíaResumen
The European Cooperation in Science and Technology (COST)
is an intergovernmental organization dedicated to funding and
coordinating scientific and technological research in Europe,
fostering collaboration among researchers and institutions
across countries. Recently, COST Action funded the "Genome
Editing to treat Human Diseases" (GenE-HumDi) network,
uniting various stakeholders such as pharmaceutical companies, academic institutions, regulatory agencies, biotech
firms, and patient advocacy groups. GenE-HumDi’s primary
objective is to expedite the application of genome editing for
therapeutic purposes in treating human diseases. To achieve
this goal, GenE-HumDi is organized in several working groups,
each focusing on specific aspects. These groups aim to enhance
genome editing technologies, assess delivery systems, address
safety concerns, promote clinical translation, and develop regulatory guidelines. The network seeks to establish standard
procedures and guidelines for these areas to standardize scientific practices and facilitate knowledge sharing. Furthermore,
GenE-HumDi aims to communicate its findings to the public
in accessible yet rigorous language, emphasizing genome editing’s potential to revolutionize the treatment of many human
diseases. The inaugural GenE-HumDi meeting, held in Granada, Spain, in March 2023, featured presentations from experts
in the field, discussing recent breakthroughs in delivery
methods, safety measures, clinical translation, and regulatory
aspects related to gene editing.